Achilles Therapeutics (ACHL)
(Real Time Quote from BATS)
$0.91 USD
+0.01 (1.11%)
Updated Jun 4, 2024 12:02 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ACHL 0.91 +0.01(1.11%)
Will ACHL be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ACHL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACHL
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
ACHL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
Other News for ACHL
Achilles Therapeutics Calls for AGM Participation
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics announces research collaboration with Arcturus
Achilles Therapeutics receives Nasdaq notice for non-compliance
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement